VBLT

VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Vascular Biogenics' (VBLT) CEO Dror Harats on Q1 2021 Results - Earnings Call Transcript

Vascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue Estimates

Vascular Biogenics's Earnings: A Preview

Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants

Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

VBL Therapeutics to Host Virtual R&D Day on April 6